Tucatinib plus trastuzumab emtansine may benefit patients with advanced or metastatic HER2-positive breast cancer
byAmerican Association for Cancer ResearchCredit: Unsplash/CC0 Public DomainA combination of two HER2-targeted drugs, tucatinib (Tukysa) and trastuzumab emtansine (Kadcyla, T-DM1), extended prog
Updated on: January 26,2024
12

Tucatinib plus trastuzumab emtansine may benefit patients with advanced or metastatic HER2-positive breast cancer
byAmerican Association for Cancer ResearchCredit: Unsplash/CC0 Public DomainA combination of two HER2-targeted drugs, tucatinib (Tukysa) and trastuzumab emtansine (Kadcyla, T-DM1), extended prog
Updated on:January 26,2024
12
